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ABSTRACT The emerging epidemic of drug resistance places the development of efficacious and safe antibiotics in the spotlight of
current research. Here, we report the design of next-generation aminoglycosides. Discovery efforts were driven by rational syn-
thesis focusing on 4= alkylations of the aminoglycoside paromomycin, with the goal to alleviate the most severe and disabling
side effect of aminoglycosides—irreversible hearing loss. Compounds were evaluated for target activity in in vitro ribosomal
translation assays, antibacterial potency against selected pathogens, cytotoxicity against mammalian cells, and in vivo ototoxic-
ity. The results of this study produced potent compounds with excellent selectivity at the ribosomal target, promising antibacte-
rial activity, and little, if any, ototoxicity upon chronic administration. The favorable biocompatibility profile combined with the
promising antibacterial activity emphasizes the potential of next-generation aminoglycosides in the treatment of infectious dis-
eases without the risk of ototoxicity.
IMPORTANCE The ever-widening epidemic of multidrug-resistant infectious diseases and the paucity of novel antibacterial agents
emerging frommodern screening platformsmandate the reinvestigation of established drugs with an emphasis on improved
biocompatibility and overcoming resistance mechanisms. Here, we describe the preparation and evaluation of derivatives of the
established aminoglycoside antibiotic paromomycin that effectively remove its biggest deficiency, ototoxicity, and overcome
certain bacterial resistance mechanisms.
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The rise in levels of antibiotic resistance has resulted in anemerging global public health crisis (1). Thus, there is an ur-
gent need not only to identify newdrug targets and to develop new
antibiotic compound classes (2) but also to improve available an-
tibacterial agents. Synthetic modification of natural product scaf-
folds has been the most successful strategy in antibacterial drug
discovery (3–5). This has led to the development of multiple gen-
erations of -lactams, macrolides, and tetracycline antibiotics.
Antibiotic scaffolds are modified to improve therapeutic use, e.g.,
by synthesizing derivatives less affected by resistance or by design-
ing derivatives with improved biocompatibility.
With the development of new orally administered antibacterial
compound classes, interest in improving the clinical efficacy of
aminoglycosides declined in the 1970s. However, aminoglycoside
antibiotics still represent one of the critically important classes of
antimicrobial agents for human therapy (6) and continue to be
used as broad-spectrum antibiotics whose targets include Gram-
negative pathogens, methicillin-resistant Staphylococcus aureus
(MRSA), multidrug-resistant Mycobacterium tuberculosis, and
complex infectious diseases such as sepsis, complicated urinary
tract infections, chronic obstructive pulmonary disease in hospi-
talized patients, and exacerbated cystic fibrosis (7, 8).
Aminoglycosides target bacterial protein synthesis by inducing
codon misreading and by inhibiting translocation of the tRNA-
mRNA complex (9–12). Aminoglycosides affect translation of the
ribosome by direct interaction with decoding A-site rRNA. The
molecular details of antibiotic-target interaction have been re-
vealed by X-ray crystallography (13, 14) and mutagenesis studies
(15, 16). Nucleotides 1408 and 1491 in the decoding A site of the
small-subunit rRNA (Escherichia coli numbering used through-
out) are critical for properly positioning ring I of the
2-deoxystreptamine aminoglycoside compounds (15–18). The
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phylogenetic variability of rRNA residues 1408 and 1491 provides
the basis and limits for aminoglycoside selectivity (19–22; for a
review, see reference 23).
The therapeutic use of aminoglycosides is compromised by
significant toxicity, in particular ototoxicity, which is irreversible
and results in hearing damage affecting 20% of patients following
brief courses of treatment (24) and more than 90% of patients
after long-term regimens (25). Ototoxicity of aminoglycoside an-
tibiotics occurs in both a sporadic, dose-dependent fashion and in
a genetically inherited fashion, the latter linked to mutations
A1555G and C1494U in mitochondrial rRNA (26–28). Recent
evidence points to a key role ofmitochondrial dysfunction in ami-
noglycoside ototoxicity (29–31).
There is a renewed interest in aminoglycosides with a focus on
overcoming resistance mechanisms (32–34; for reviews, see refer-
ences 35, 36, and 37). Few, if any, systematic studies have been
conducted to discover aminoglycoside structures with less ototox-
icity. Previous studies led to the hypothesis that aminoglycoside
ototoxicity is related to the drug’smechanism of action and linked
to limited target selectivity, i.e., it stems from the drug’s action on
the eukaryotic ribosome (29, 38). Following this line of research,
we recently disclosed the discovery of a highly target-selective set
of novel 4=,6=-O-acetals and 4=-O-aralkyl-ethers of the clinical
aminoglycoside paromomycin (1), which are active against a
range of bacterial pathogens (39). Despite these initial promising
results at the drug target level, subsequent validation in vivo
pointed to dose-related acute toxicity (unpublished data). Given
our previous success in modifying the drug-target interaction, we
were interested in exploring further novel 4=-aminoglycoside an-
alogues with a view to combining target selectivity with amelio-
rated ototoxicity and antibacterial efficacy. Here, we report on the
design and synthesis of 4=-O-(alkyl) substituted derivatives of
paromomycin. The ribosomal target selectivity, antibacterial effi-
cacy, and toxicity profile of these compounds, which are devoid of
the acute toxicity exhibited by the previous aralkyl series, were
examined in both in vitro and in vivo systems. Lead structures,
exhibiting enhanced selectivity for the bacterial ribosome, potent
antibacterial activity, and little, if any, ototoxicity in vivo were
identified.
RESULTS
Chemical synthesis and target specificity. Ring I of paromomy-
cin was modified by substitutions of the 4=-hydroxy group. We
designed a series of aliphatic 4=-O-substituted compounds, com-
pounds 9 to 22, derived from the known paromomycin derivative,
compound 2, via the intermediates, compounds 23 to 27 (Fig. 1;
see also the supplemental material). The derivatives were tested
for target activity in cell-free ribosomal translation assays in com-
parison to the parental paromomycin, 4=-deoxy paromomycin
(40), 4=-O-(3-phenylpropyl) paromomycin, and 4=,6=-O-(3-
phenylpropylidene) paromomycin—the latter two compounds as
representatives of the previous series of 4=-O-aralkyl ethers and
4=,6=-O-acetals (39). To assess target activity in cell-free transla-
tion assays, we used wild-type bacterial ribosomes and recombi-
nant bacterial ribosomes with single point mutations in the drug
binding pocket. Dose-response curves of aminoglycoside-
dependent inhibition of luciferase synthesis were analyzed to de-
fine the drug concentrations required to inhibit in vitro synthesis
of functional firefly luciferase to 50% (IC50s).
The point mutations introduced into the bacterial ribosomes
were chosen to reflect the phylogenetically variable 16S rRNA res-
idues in the drug binding pocket, i.e., nucleotides 1408 (adenine in
bacterial/mitochondrial ribosomes and guanine in cytosolic ribo-
somes) and 1491 (guanine in bacterial ribosomes, adenine in cy-
tosolic ribosomes, and cytosine in mitochondrial ribosomes [see
Fig. S1 in the supplemental material]) in the decoding A site. In-
teraction of paromomycin with the ribosome is little affected by
alteration of A1408, whilemutational alterations of residueG1491
significantly decrease drug-target interaction. The interaction of
the 4=-O-alkyl derivatives with the ribosomal drug binding site,
however, largely involves both residues 1408 and 1491 (Table 1).
This is illustrated by comparing the drug susceptibility of mutant
ribosomes with that of wild-type ribosomes and by calculating the
ratio of the IC50 for themutant ribosomes to that for the wild-type
ribosomes. For paromomycin, the ratio of the IC50 for the G1408
mutant ribosomes to the IC50 for the wild-type ribosomes is 13,
and the ratio of the IC50 for the C1491 mutant ribosomes to the
IC50 for the wild-type ribosomes is 520. For compound 11, the
ratio of IC50s for the G1408 mutant ribosomes to the wild-type
ribosomes is 80, and the ratio of IC50s for C1491 mutant ribo-
somes to the wild-type ribosomes is 2,000; for compound 10, the
ratio of IC50s for the G1408 mutant ribosomes to the wild-type
ribosomes is 100, and the ratio of IC50s for the C1491 mutant
ribosomes to the wild-type ribosomes is 3,000.
Compared to a simple deletion of the 4=-hydroxy group as in
4=-deoxy paromomycin, introduction of a 4=-O-alkyl group pro-
vokes a substantial loss of activity against mutant 1491C, 1491A,
and 1408G ribosomes. The optimum size for the 4=-O-alkyl group
conferring little change in activity toward bacterial wild-type ri-
bosomes but greatly affecting interaction with mutant 1491A,
1491C, and 1408G ribosomes is two or three carbon atoms. The
effect of the 4=-O-alkyl substituent is in part offset by the inclusion
of a hydroxyl group, as in the 2-hydroxy alkyl ether compounds
(compounds 16 and 17). Shift of the methoxymethyl group from
the 4= position to the 6= position causes a significant loss of inhib-
itory activity for wild-type bacterial ribosomes (e.g., compare
compound 9 with compound 19). Addition of two methoxy-
methyl groups (one at 4=-O and the other at 6=-O) as in compound
20 totally disrupts antiribosomal activity.
Antibacterial activity. To screen for antibacterial activity, we
first determined theMIC values againstMycobacterium smegmatis
(see Table S1 in the supplemental material). Themost active com-
pounds were selected and further tested against clinical isolates of
Escherichia coli and Staphylococcus aureus. Compared to the pa-
rental paromomycin, the antibacterial activity of the 4=-O-
alkylated aminoglycosides was mostly modest (Table 2). How-
ever, the ethyl ether (compound 10) and propyl ether (compound
11) showed promising antibacterial activity including clinical
S. aureus isolates that are highly resistant toward paromomycin.
To determinewhether the in vitro activity of the designed com-
pound series translates into in vivo activity, we assessed the anti-
bacterial activity of the ethyl ether (compound 10) and propyl
ether (compound 11) in a neutropenic murine model of Staphy-
lococcus aureus septicemia. Two different routes of drug applica-
tion were initially investigated—intravenous and subcutaneous.
In animals infected with methicillin-resistant S. aureus, treatment
with compounds 10 and 11 via both routes effectively reduced the
bacterial burden in blood and kidney in a dose-dependentmanner
(Fig. 2). For subcutaneous drug application, the efficacy of com-
pounds 10 and 11 was compared to that of the parental paromo-
Duscha et al.
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mycin. Compared to the vehicle-treated mice, drug treatment re-
duced bacterial burden in the kidney between 2 and 7 log10 units
and in blood between 2 and 3 log10 units in a dose-dependent
manner. At the highest dose tested, compounds 10 and 11 and
paromomycin reduced the bacterial burden in the kidney below
detectable limits (Fig. 2C and F).
Activity toward eukaryotic ribosomes and cell cytotoxicity.
The toxicity of aminoglycosides, at least in part, relates to limited
selectivity, i.e., their activity toward the eukaryotic ribosome (20).
The two characteristic features of aminoglycoside action on the
eukaryotic ribosome relevant in this respect are translation inhi-
bition and induction of misreading (23).
To assess target selectivity of the 4=-O-alkyl derivatives, i.e.,
their interaction with the various eukaryotic drug binding pock-
ets, we made use of hybrid bacterial ribosomes carrying decoding
A-site cassettes representing the various eukaryotic drug binding
pockets. These ribosomes carry the cytoplasmic A site, mitochon-
drial A site, or mitochondrial mutant A1555G deafness A site (see
Fig. S1 in the supplemental material) and have been shown to
faithfully reflect the drug susceptibility of the corresponding eu-
karyotic ribosomes (21, 29, 30). Translation inhibition was as-
sessed by determining the inhibition of protein synthesis in cell-
free translation assays. Compared to paromomycin, the 4=-O-
alkyl derivatives interact poorly with any of the eukaryotic drug
FIG 1 Chemical structures of compounds synthesized. The compounds are indicated by boldface numbers (e.g., compound 1 is shown as 1).
Next-Generation Aminoglycosides
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binding pockets, including cytosolic hybrid ribosomes, mito-
chondrial hybrid ribosomes, and mitochondrial deafness hybrid
ribosomes (Table 3).
To study aminoglycoside-induced misreading, we used a sen-
sitive gain-of-function assay taking advantage of recombinant
firefly luciferase constructs where amino acid 245 in the active site
of firefly luciferase has beenmutated fromwild-type CAC (His) to
the near-cognate codon CGC (Arg). The CAC-to-CGC mutation
results in loss of enzymatic activity, and enzymatic activity can be
restored by aminoglycoside-induced misreading of the near-
cognate CGC codon (30). On the basis of aminoglycoside-
induced misreading and drug-mediated inhibition of transloca-
tion, we calculated a ribosomal damage index (RDI) by relating
inhibition of eukaryotic protein synthesis (IC50) and induction of
ribosomalmisreading (1/IC50misreading at IC50/misreading in
the absence of the drug 100). Compared to the parental scaffold
paromomycin, compounds 22, 10, and 11 show a significantly
lower ribosomal damage index for all three hybrid ribosomes—
cytosolic hybrid, mitochondrial hybrid, and mitochondrial
A1555G mutant hybrid (Table 4). To challenge the results of the
hybrid ribosomes, we determined the RDI for native cytosolic
eukaryotic ribosomes. Rabbit reticulocyte ribosomes were used,
and the RDI values were compared to those of the cytosolic hybrid
ribosomes. An excellent correlation (Pearson correlation coeffi-
cient, R  0.998) corroborated our conclusion that the designed
aminoglycosides are less toxic toward eukaryotic ribosomes.
Aminoglycoside-mediated dysfunction of the eukaryotic ribo-
some may manifest as drug cytotoxicity in mammalian cells (21,
29, 41). The cytotoxicity of compounds 22, 10, and 11 was deter-
mined. Compared to Geneticin, an aminoglycoside known to be
TABLE 1 Interaction of 4=-O-alkyl derivatives with polymorphic residues 1408 and 1491 in the drug binding pocket
Drug IC50 (mg/liter) with mutant bacterial A sites in the ribosomea:
Wild-type G1491C G1491A A1408G
Paromomycin 0.02 0.01 10.42 2.86 0.57 0.09 0.26 0.04
4= Deoxy paromomycin 0.05 0.01 28.6 0.9 2.4 0.1 0.89 0.4
4=,6=-O-(3-Phenylpropylidene)
paromomycin
0.10 0.03 124.1 0.1 43.0 11.3 3.8 2.4
4=-O-(3-Phenylpropyl)
paromomycin
0.20 0.07 200.73 25.84 51.26 15.72 14.52 5.77
Compound 13 0.40 0.11 229.92 32.26 62.13 9.35 21.73 5.04
Compound 12 0.30 0.03 348.38 23.69 90.87 16.44 24.33 5.82
Compound 11 0.14 0.02 288.85 148.66 45.54 23.65 11.74 4.94
Compound 14 0.14 0.04 268.65 18.91 44.68 3.15 12.34 1.57
Compound 10 0.08 0.03 258.93 31.67 40.77 16.93 8.83 3.10
Compound 22 0.12 0.08 180.47 45.33 41.77 7.39 5.42 1.23
Compound 9 0.22 0.05 242.42 6.20 68.99 11.53 14.21 6.74
Compound 21 0.89 0.24 522.20 44.59 119.58 49.65 32.57 9.13
Compound 16 0.05 0.02 152.22 51.28 5.99 1.19 1.93 0.38
Compound 15 0.73 0.19 700 143.69 15.86 38.12 5.73
Compound 17 0.03 0.01 67.35 21.25 2.57 0.48 0.87 0.07
Compound 18 0.20 0.03 167.43 11.30 11.45 0.55 4.48 0.32
Compound 19 1.57 0.42 585.91 16.81 83.71 18.04 5.47 1.24
Compound 20 10.87 0.53 700 529.40 76.03 80.44 20.17
a The interaction of 4=-O-alkyl derivatives with the bacterial A site of the drug binding pocket is measured by the drug concentrations (in milligrams per liter) required to inhibit in
vitro synthesis of functional firefly luciferase to 50% (IC50s). The values are means standard deviations (SD) for experiments performed in triplicate.
TABLE 2 MICs of clinical isolates
Clinical isolate MIC (mg/liter)a:
Paromomycin c12 c11 c14 c10 c22 c9 c16 c17 c18
Staphylococcus
aureus (MRSA)
isolates
AG 038 4 816 816 816 816 3264 32 32 1632 1632
AG 039 256 1632 16 16 16 64128 32 32 1632 64
AG 042 256 16 816 16 816 32 32 1632 16 32
AG 044 48 16 8 816 816 3264 32 3264 32 1632
AG 045 4 16 8 816 816 1632 32 1632 16 32
Escherichia coli
isolates
AG 002 816 3264 1632 64 32 128 128 32 1632 3264
AG 003 816 64 32 64 32 64128 128 32 16 64128
AG 001 1632 64 32 64 64 128 128 3264 3264 128
AG 055 816 64 32 64 32 64 128 3264 1632 64128
a Compounds 9 to 22 are indicated by a lowercase c before the compound number (e.g., c12 stands for compound 12).
Duscha et al.
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cytotoxic tomammalian cells, there was no detectable cytotoxicity
of compound 22, 10, or 11 against mammalian NIH 3T3 cells (see
Fig. S2 in the supplemental material).
We performed an extensive in vitro profiling screen of com-
pounds 10 and 11 against 44 primary human molecular targets
(42) to detect any relevant off-target pharmacological effects.
With the possible exception of Lck kinase, no significant off-target
effects were observed, including hERGpotassium ion channel and
G-protein-coupled receptors (see Table S2 in the supplemental
material). In addition, the compounds show low plasma protein
binding properties (the mean values for percent protein bound
were 13% for compound 10 and 9% for compound 11).
In vivo ototoxicity. The guinea pig model of chronic ototox-
icity is the reference for determination of aminoglycoside-
induced hearing loss in vivo (24). We used this model to compare
the ototoxicity of compounds 10 and 11 to that of the standard
gentamicin. Notably, the acute toxicity that prevented such stud-
ies in the previous aralkyl series is absent from the present class of
compounds. Guinea pigs were treated for 2 weeks with various
doses of aminoglycosides, and ototoxicitywas assessed bymeasur-
ing hearing thresholds at 12 kHz and 32 kHz using auditory brain
stem responses (ABR). Gentamicin-induced threshold shifts (i.e.,
loss of auditory function) exhibit a steep dose-response curve—
little effect at 100 mg of gentamicin/kg of body weight but com-
plete deafness at 160mg gentamicin/kg. Experiments with 180mg
gentamicin/kg were discontinued after the premature death of
two animals. In contrast, treatment with compounds 10 and 11
showed no effect on ABR thresholds, even at doses as high as
400 mg/kg (Fig. 3A). A modest but significant threshold shift at
32 kHz was observed for compound 10 at 400 mg/kg (see Ta-
FIG 2 In vivo activity of aminoglycoside compounds and comparators in a murine septicemia model. Compounds were administered intravenously (IV) (A
and D) or subcutaneously (SC) (B, C, E, and F). Compounds 10 and 11 are indicated by boldface numbers. (A to C) Bacterial burden in kidney (CFU/g tissue);
(D to F) bacterial burden in blood (CFU/ml). The values for 1 h pretreatment and vehicle (25 h) are shown as controls. Each symbol represents the value for an
individual animal (CFU). The bar represents the geometric mean of the group (5 mice per treatment group). The log reduction (LogR) compared to the vehicle
control and the P value (nonparametric Kruskal-Wallis using pairwise comparisons [Conover-Inman]) are given above each group (NS, not significant). The
limit of detection is indicated by the horizontal line labeled LOD. The different treatments are color coded as follows: light gray, pretreatment; dark gray, vehicle
control; red, compound 10; orange, compound 11; blue, paromomycin; violet, linezolid.
Next-Generation Aminoglycosides
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ble S3 in the supplemental material). In order to correlate the
functional hearing data with histopathology, we quantified loss of
outer hair cells in cochleae harvested after theABRmeasurements.
Loss of hair cells seen in cochlear surface preparations was in
agreement with the functional results obtained from the ABR
measurements (Fig. 3B). In animals treated with 140mg gentami-
cin/kg, extensive loss of outer hair cells was seen at the base of the
cochlea, consistent with the observed high-frequency hearing loss.
In contrast, in animals treated with 400mg of compound 10 or 11
per kg, little (compound 10) or no (compound 11) loss of outer
hair cells was found.
DISCUSSION
Here, we have approached the development of new lead antibac-
terial agents through the informed modification of an existing
compound class and accomplished the synthesis of potent amino-
glycoside compounds devoid of ototoxic side effects. Aminogly-
coside antibiotics offer several features that make them an attrac-
tive target for further development: high efficacy, potent
bactericidal activity, lack of drug-related allergy, and absence of
life-threatening side effects related to disturbances of the human
microbiome, e.g., postantibiotic enterocolitis (7). Thus, we fol-
lowed the idea to substantially improve aminoglycoside antibiot-
ics with their potent broad-spectrum activity against many clini-
cally relevant resistant pathogens and to render them more
broadly applicable by engineering out their biggest deficiency,
ototoxicity.
Few systematic attempts have been undertaken to design
more-biocompatible aminoglycosides. Our approach is based on
the mechanistic hypothesis that the toxic side effects of aminogly-
cosides are related to limitations in ribosomal target selectivity
(29–31, 38). On the basis of this hypothesis, we have recently dis-
closed a set of new aminoglycosides by optimizing the structure-
activity relationship of the paromomycin scaffold toward in-
creased target selectivity (39). Here, we report on further
optimizing the C-4=-O-substituent toward improved biocompat-
ibility by ameliorating toxicity. We demonstrate that the critical
C-4=-alkoxy moieties identified confer substantial antibacterial
activity in vitro and in vivo accompanied by little, if any, hearing
loss or morphological cochlear damage. In addition, there was no
detectable cytotoxicity against mammalian cells.
Compared to the parental paromomycin, introduction of a
4=-O-alkyl group—with an optimum size of two or three car-
bons—affords only a slight loss of activity toward wild-type bac-
terial ribosomes but offers a substantial increase in selectivity. The
TABLE 3 Interaction of 4=-O-alkyl derivatives with eukaryotic drug binding pockets
Drug IC50 (mg/liter) with eukaryotic A sites in the ribosomea:
Mitochondrial
wild-type
Mitochondrial
mutant A1555G Cytosolic wild-type Rabbit reticulocytes
Paromomycin 50.66 13.33 5.77 2.32 9.89 2.73 9.55 4.94
4= Deoxy paromomycin 74.1 12.4 24.2 10.5 28.4 13.8 17.3 4.2
4=,6=-O-(3-Phenylpropylidene)
paromomycin
305.7 74.1 126.9 54.4 150.5 28.0 ND
4=-O-(3-Phenylpropyl)
paromomycin
49.85 15.39 105.68 39.23 268.57 54.97 ND
Compound 13 109.02 6.73 81.11 8.77 92.32 9.20 49.74 3.48
Compound 12 149.54 38.62 148.36 30.59 161.48 13.93 49.83 5.47
Compound 11 194.88 57.17 151.92 31.44 165.52 28.30 59.93 30.10
Compound 14 102.39 9.99 90.88 9.96 125.18 3.07 49.98 16.75
Compound 10 96.82 4.22 119.83 45.62 94.65 30.97 37.58 14.14
Compound 22 206.31 112.31 98.00 39.68 126.41 71.71 37.40 4.61
Compound 9 106.58 24.30 174.76 46.48 128.22 27.65 40.92 8.39
Compound 21 325.05 123.72 252.74 37.61 240.92 69.84 130.03 41.37
Compound 16 87.49 30.97 81.35 17.06 74.36 11.94 24.00 5.10
Compound 15 700 700 700 374.34 117.07
Compound 17 31.84 14.21 24.32 3.30 25.54 2.30 8.81 4.42
Compound 18 68.24 5.66 46.90 4.07 89.83 4.87 43.10 1.88
Compound 19 504.69 107.23 288.80 10.81 171.37 22.52 91.19 18.69
Compound 20 700 700 482.63 58.51 90.97 8.00
a The interaction of 4=-O-alkyl derivatives with the eukaryotic drug binding pocket is measured by the drug concentrations (in milligrams per liter) required to inhibit in vitro
synthesis of functional firefly luciferase to 50% (IC50s). The values are means standard deviations (SD) for experiments performed in triplicate. ND, not determined.
TABLE 4 Ribosomal damage index
Drug Ribosomal damage indexa
Mitochondrial
wild-type
Mitochondrial
mutant A1555G
Cytosolic
wild-type
Rabbit
ribosomes
Paromomycin 5.0 125.0 40.0 120.0
Compound 22 0.4 2.5 2.5 10.5
Compound 10 0.8 2.0 2.0 16.5
Compound 11 1.5 1.5 3.0 14.0
a The ribosomal damage index is calculated as follows: 1/IC50misreading at IC50/misreading in the absence of the drug 100.
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target selectivity profile of the novel 4=-alkoxy compounds com-
pares favorably to that of the former 4=,6=-O-acetals and 4=-O-
aralkyl ether derivatives. Modeling the drug-target interaction of
the 4= alkoxy compounds and the ribosomal A site on the basis of
available crystal structures of 4=-O-acetals and 4=-O-ethers in
complex with the small ribosomal subunit of Thermus thermophi-
lus (39) suggests that the 4= substituent is positioned in proximity
to the backbone and ribose of A1492 and points out into the bulk
solvent betweenA1492 andG1491 (see Fig. S3 in the supplemental
material). At the ribosomal drug target level, the series of aliphatic
4=-O-alkylated 4,5-disubstituted 2-deoxystreptamines largely
avoids interaction with the eukaryotic drug binding pockets in
cytosolic andmitochondrial ribosomes (Table 3).Most likely, this
reflects the susceptibility of the current compound series to base
substitutions at polymorphic 16S rRNA residues 1408 and 1491 in
the drug binding pocket, as revealed by the interaction with re-
combinant bacterial ribosomes carrying the corresponding point
mutations (Table 1). Thus, compared to the parental paromomy-
cin, the 4=-O-alkyl derivatives take additional advantage of the
polymorphic rRNA residues to increase target selectivity. Alkyla-
tion of the 4=-OH of the parental paromomycin tends to decrease
antibacterial efficacy. However, compared to the initially synthe-
sized compounds, theMIC values of the subsequently synthesized
compounds 10 and 11 demonstrate rather potent antibacterial
activity (Table 2), indicating that there is opportunity to further
enhance antibacterial activity of 4=-O-substituted compounds.
The determination of aminoglycoside ototoxicity requires the
assessment of auditory function in vivo. Although the guinea pig
model of chronic ototoxicity requires the synthesis of large
amounts of compound, it is unequivocally considered the gold
standard, which best reflects the pathophysiology involved in hu-
man aminoglycoside-induced ototoxicity (24). The minimal oto-
toxicity of the designed compounds, predicted on the basis of their
in vitro ribosomal damage index, is clearly demonstrated in vivo.
There was very little hearing loss induced by compound 10 or 11,
even at excessive drug concentrations. This is in stark contrast to
the well-characterized and commonly used aminoglycoside gen-
tamicin, which caused significant auditory threshold shifts. Con-
sistent with the functional results fromABRmeasurements, the in
vivo treatment with the newly designed aminoglycosides resulted
in little or no hair cell loss. In addition to ototoxicity, treatment
with gentamicin also resulted in signs of general toxicity, most
likely reflecting nephrotoxicity, i.e., significantweight loss at doses
below 160 mg/kg, and death upon doses exceeding 160 mg/kg. In
contrast, compounds 10 and 11 were well tolerated. All animals
treated with compound 10 or 11 remained healthy during the
complete course of the experiment. No drug-related death or
weight loss was observed even at doses of 400 mg/kg body weight.
Analysis of blood urea nitrogen and creatinine likewise did not
reveal any nephrotoxic side effects of the compounds. Notably,
the concentrations of drugs used in the animalmodel exceed those
used in clinical medicine by an order of magnitude so as to obtain
FIG 3 Loss of auditory function and hair cells in vivo. (A) Effect of chronic aminoglycoside treatment in vivo on ABR at 12 kHz. The threshold shift is the
difference in the auditory threshold before and 3 weeks after treatment, calculated for individual animals. The threshold shift is given in decibels (dB) and
corresponds to a logarithmic scale, i.e., a 10-dB difference indicates a difference in energy of 1 log10 unit. The different treatments are indicated as follows: black
bars, control; gray bars, gentamicin; white bars outlined in black, compound 10; white bars outlined in gray, compound 11. Data represent means plus standard
errors of the means (SEM) (error bars) (n  3 to 11 per drug concentration). (B) Quantitative evaluation of hair cell loss. Surface preparations of guinea pig
cochlea were evaluated quantitatively by determining the presence or absence of hair cells along the entire length of the cochlea. Representative examples are
shown. Red, green, and blue lines indicate outer hair cells from the first, second, and third row, respectively. y axis, missing hair cells (%); x axis, distance from
apex (mm). (a)Control (nodrug treatment). Typical low-level scattered loss of individual cells along the length of the cochleawas observed. (b)Gentamicin given
at 140 mg/kg. A steep rise of hair cell loss from the middle cochlea to complete loss at the base was seen. (c) Compound 10 given at 400 mg/kg. There was some
hair cell loss but only at the very base of the cochlea. (d) Compound 11 given at 400 mg/kg. There was no significant hair cell loss.
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relatively high and reliable drug levels in serum, resulting in con-
sistent ABR threshold shifts.
The rationale for choosing the 4= position formodificationwas
suggested by the target selectivity profile observed with the previ-
ously synthesized 4=,6=-O-acetals and 4=-O-aralkyl-ethers (39).
Our data extend these findings and demonstrate a key role for
4=-substituents in determining drug toxicity. We have found that
4=-O-alkylation is a valuable structural element that significantly
affects target selectivity and ototoxicity. In addition, extensive in
vitro testing against mammalian enzymes and receptors showed
that the 4=-alkoxy leads have little potential for off-target effects
that result in adverse reactions. Our combined chemical synthesis,
biochemical, and toxicology studies have identified 4=-alkoxy
groups of paromomycin as a promising new pharmacophore that
affects aminoglycoside ototoxicity and significantly improves bio-
compatibility. These efforts validate the potential to modify the
neamine core of the aminoglycosides to obtain potent new sets of
this compound class that are less compromised by adverse side
effects. Together with strategies to increase the antibacterial effi-
cacy of these compounds and their recalcitrance against resistance
determinants (32, 33, 43, 44; for a review, see reference 45), this
should result in a revival of this important class of antibacterials in
combating the global emergence of antibiotic resistance.
MATERIALS AND METHODS
Antibiotic compounds. Paromomycin was obtained from Sigma. Chem-
ical synthesis procedures, including Schemes 1 to 4, are detailed in Text S1
in the supplemental material.
Bacterial strains. Clinical isolates of Escherichia coli and Staphylococ-
cus aureus were obtained from the Diagnostic Department, Institute of
MedicalMicrobiology,University of Zurich.MIC valueswere determined
by brothmicrodilution assays.Microtiter plates were incubated overnight
for E. coli and S. aureus and 72 h forMycobacterium smegmatis.
Recombinant microorganisms. The construction of these strains de-
rived from an M. smegmatis rrnB strain with a single rRNA operon has
been described previously (21, 28).
Purification of ribosomes and cell-free translation assays. Ribo-
somes were purified from bacterial cell pellets, and purified 70S hybrid
ribosomes were used in translation reaction mixtures as described previ-
ously (30). A typical translation reaction mixture with a total volume of
30 l contained 0.25 M 70S ribosomes, 4 g firefly luciferase (F-luc)
mRNA, 40% (vol/vol) M. smegmatis S100 extract, 200 M amino acid
mixture, 24 units of RiboLock (Thermo Scientific), and 0.4 mg ml1
tRNAs, and energy was supplied by addition of 12 l of commercial S30
Premix without amino acids (Promega). In addition to ribosomes, rabbit
reticulocyte lysate (Promega) was used for in vitro translation. Following
addition of serially diluted aminoglycosides, the reaction mixture was
incubated at 37°C for 35 min and stopped on ice. Thirty-microliter sam-
ples of the reactionmixture were assayed for luciferase activities using the
Dual-Luciferase reporter assay system (Promega). Luminescence was
measured using a luminometer FLx800 (Bio-Tek Instruments).
Misreading was assessed in a gain-of-function assay as described pre-
viously (30). In brief, we introduced Arg245 (CGC, near-cognate codon)
into the firefly luciferase protein to replace residue His245 (CAC codon).
Arg245 F-lucmRNA andwild-type (wt) F-lucmRNAwere used in in vitro
translation reaction mixtures, and renilla luciferase (R-luc) mRNA was
used as internal control. We quantified misreading by calculating mutant
firefly/renilla luciferase activity compared with wild-type firefly/renilla
luciferase activity.
Cytotoxicity assays. For cytotoxicity assays, mouse embryonic fibro-
blast (NIH 3T3) cells were grown in 96-well plates (4,000 cells/well) in
Dulbecco modified Eagle medium (DMEM) containing 10% fetal bovine
serum (FBS) and 1%glutamine at 37°C and 5%CO2. Following overnight
incubation, serial dilutions of compound were added, and the cells were
incubated for an additional 72 h. Cell viability was measured using ala-
marBlue fluorimetric assay (Life Technologies) according to the manu-
facturer’s instructions. Fluorescence was measured using an FLx800 plate
reader (Bio-Tek Instruments). Cell viability was calculated as the ratio
between the numbers of living cells in cultures grown in the presence of
the tested compounds and those in cultures grown under identical con-
ditions without the tested compound. The LC25 values, i.e., the drug con-
centration at which 25% of the cells in culture are nonviable, were calcu-
lated from fitting concentration-response curves to the data of at least
three independent experiments using PRISM 5 software.
In vivo infection experiments. Animal experiments were performed
under United Kingdom Home Office Licenses with clearance by the eth-
ical review committee at the University of Manchester. Male mice aged 7
to 8weeks oldwere used in this study.Micewere supplied byCharles River
United Kingdom and were specific pathogen free. The strain of mouse
used was Hsd:ICR (CD-1), a well-characterized outbred strain. The
weight of the mice at the start of the experiment was 22 to 25 g. Mice were
housed in sterile individual ventilated cages with free access to sterile food
and water and were exposed to 12-h light/dark cycles with dawn/dusk
phases. There were five mice in each group.
Mice were rendered temporarily neutropenic by immunosuppression
with cyclophosphamide at 200 mg/kg 4 days before infection and
150mg/kg 1 day before infection by intraperitoneal injection. The immu-
nosuppression regimen leads to neutropenia starting 24 h after the ad-
ministration of cyclophosphamide, and neutropenia continues through-
out the study. For in vivo infection, a methicillin-resistant strain of
Staphylococcus aureus, clinical isolate MRSA AG041, was used. Twenty-
four hours after the second round of immunosuppression, mice were
infected with S. aureus MRSA AG041 by intravenous injection into the
lateral tail vein using ~1 107 CFU/mouse. This strain had the following
MIC values—4.0mg/liter for paromomycin, 8mg/liter for compound 10,
16 mg/liter for compound 11, and 1.0 mg/liter for linezolid. Test com-
pounds and comparators were reconstituted and diluted in 0.9% saline.
Dosing solutions were prepared immediately prior to administration of
the first dose and stored at 4°C between treatments. Antibacterial treat-
ment was initiated 1 h postinfection; linezolid at a dose of 20 mg/kg was
used as a positive control and was always given by intravenous bolus
injection. All drugs were administered 1, 9, and 17 h postinfection.
At 1 h (pretreatment group) or 24 h postinfection, blood samples were
collected by cardiac puncture under isoflurane anesthesia, and mice were
humanely euthanized using pentobarbitone overdose. Both kidneys were
removed and homogenized in 2 ml ice-cold sterile phosphate-buffered
saline (PBS). Kidney homogenates were quantitatively cultured onto
mannitol salt agar (MSA) and incubated at 37°C for 24 h before being
counted. Individual blood samples were quantitatively cultured onto cys-
teine lactose electrolyte-deficient (CLED) agar and incubated at 37°C for
24 h before being counted. Data were analyzed, using StatsDirect software
(version 2.7.8), using the nonparametric Kruskal-Wallis test (pairwise
comparisons, Conover-Inman).
In vivo ototoxicity. Male Hartley guinea pigs of initially about 200 g
body weight (Charles River Breeding Laboratories) had free access to wa-
ter and food and were acclimated for 1 week prior to experiments. Drugs
were administered once daily subcutaneously for 14 days at dosages indi-
cated in the figure legends; saline injections of the same volume served as
controls. Auditory function was measured as auditory brain stem re-
sponse (ABR) at 12 and 32 kHz under anesthesia with an intraperitoneal
injection of xylazine (7 mg/kg body weight), ketamine (65 mg/kg), and
acepromazine (2 mg/kg). Each animal had its threshold determined be-
fore and 3 weeks after the end of drug treatment.
Following the final ABR, cochleae were harvested and dissected into
segments from the apical, middle, and basal turns. These segments were
permeabilized in 3% Triton X-100 for 30 min at room temperature (RT),
washed three times with PBS, and incubated with rhodamine phalloidin
(1:100) at RT for 1 h. Hair cells were counted on a Leitz Orthoplan mi-
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croscope whose right objective had a 0.19-mm scale imposed on the field.
Beginning at the apex, consecutive 0.19-mm fields were evaluated by ob-
servers in a blindmanner (unaware of the experimental conditions). Hair
cell counts were compared to a normative database (KHRI Cytocochleo-
gram, version 3.0.6; Kresge Hearing Research Institute).
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